Search

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Presidential Speakers

Promising crucial developments in the field of hematology, the speakers and presentation topics of the EHA2025 Presidential Session speakers are now available.  

Friday, June 13, 2025 - Presidential Session I

Immunotherapy (TCR related)

Prof.

Read more

How malignant cells in patients with Chronic Lymphocytic Leukemia escape T cell recognition and attack

T cell activation is essential for immunity including the recognition and killing of abnormal target cells such as cancerous cells.

Read more

TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS

Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.

Read more

Words of wisdom

Do you ever wonder what established leaders in the field would tell their younger selves? We have asked this question for you! Every month we bring to you a unique career perspective from people who have once been in your…

Read more

COVID-19 Expert opinions

Expert opinions for hematologists in COVID-19 crisis
COVID-19, caused by SARS-CoV-2, is expected to be a devastating infection in many patients with hematologic diseases.

Read more

Highlights from the SWG

SWG session at EHA2023The EHA2023 Congress was held in Frankfurt, Germany, in June 2023. As part of this event, the SWG held a session on Saturday, June 10, 2023. Title‘Stem cells: Clonal and mutational dynamics of hematopoietic stem cells.

Read more